535170-20-8

Basic information

• Product Name: CarbaMic acid, (3-aMino-2,6-difluorophenyl)-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, (3-aMino-2,6-difluorophenyl)-, 1,1-diMethylethyl ester;tert-Butyl (3-amino-2,6-difluorophenyl)carbamate
• CAS NO: 535170-20-8
• Molecular Formula: C₁₁H₁₄F₂N₂O₂
• Molecular Weight: 244.2378664
• Mol File: 535170-20-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 270.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.291±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 11.40±0.70(Predicted)
• CAS DataBase Reference: CarbaMic acid, (3-aMino-2,6-difluorophenyl)-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, (3-aMino-2,6-difluorophenyl)-, 1,1-diMethylethyl ester(535170-20-8)
• EPA Substance Registry System: CarbaMic acid, (3-aMino-2,6-difluorophenyl)-, 1,1-diMethylethyl ester(535170-20-8)

Safety Data

• Hazardous Substances Data: 535170-20-8(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (3-amino-2,6-difluorophenyl)-, 1,1-dimethylethyl ester, is a synthetic chemical compound. It contains a variety of elements including carbon, hydrogen, nitrogen, oxygen and fluorine. Carbamic acid, (3-amino-2,6-difluorophenyl)-, 1,1-dimethylethyl ester features a carbamic acid group, which is composed of an amino group bonded to a carbonyl group, attached to a difluorophenyl group, which is a phenyl group substituted with two fluorine atoms. Its other segment is a 1,1-dimethylethyl ester unit. The detailed chemical properties, such as its reactivity or toxicity, are not widely studied or reported. As with all chemical compounds, handling should be done while exercising caution until more concrete information is obtained.

InChI:InChI=1S/C11H14F2N2O2/c1-11(2,3)17-10(16)15-9-6(12)4-5-7(14)8(9)13/h4-5H,14H2,1-3H3,(H,15,16)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 25892-09-5 2,6-difluoro-3-nitroaniline 
• 385-00-2 2,6-difluorobenzoic acid 
• 260552-98-5 2,6-difluoro-3-nitrobenzoic acid chloride 
• 83141-10-0 2,6-difluoro-3-nitrobenzoic acid 
• 535170-17-3 tert-butyl (2,6-difluoro-3-nitrophenyl)carbamate 

Relevant articles and documents

PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF

The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.

Discovery of a highly specific and potent pan-RAF inhibitor

We describe the structure-based design and synthesis of N-(2,6-difluorophenyl)-3-(9H-purin-6-yl)pyridine-2-amine derivatives as a selective pan-RAF kinase inhibitor. The synthesized compounds showed highly potent and specific inhibition of the BRAFV600E mutant cell line. Among them, N-(3-((3-(9H-purin-6-yl) pyridine-2-yl)amino)-2,4-difluorophenyl)furan-3-sulfonamide (4b) exhibited the most potent inhibitory activities against protein kinase enzymes BRAFV600E, BRAFWT, and CRAF (IC50 of 2, 2, and 1 nM, respectively) and a mutant cell line bearing a BRAFV600E mutation, A375P (GI50 of 7 nM).

A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group

Fluoroquinolones represent a major class of antibacterial agents with great therapeutic potential. In this study, we designed m-aminophenyl groups as novel N-1 substituents of naphthyridones and quinolones. Among newly synthesized compounds, 7-(3-aminoazetidin-1-yl)-1-(5-amino-2,4-difluorophenyl)-8-chloro-6- fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4) has extremely potent antibacterial activities against Gram (+) as well as Gram (-) bacteria. This compound is significantly more potent than trovafloxacin against clinical isolates: 30 times against Streptococcus pneumoniae and 128 times against methicillin resistant Staphylococcus aureus. The structure-activity relationship (SAR) study revealed that a limited combination of 1-(5-amino-2,4-difluorophenyl) group, 7-(azetidin-1-yl) group, and 8-Cl atom (or Br atom or Me group) gave potent antibacterial activity. An X-ray crystallographic study of a 7-(3-ethylaminoazetidin-1-yl)-8-chloro derivative demonstrated that the N-1 aromatic group was remarkably distorted out of the core quinolone plane by steric repulsion between the C-8 Cl atom and the N-1 substituent. Furthermore, a molecular modeling study of 4 and its analogues demonstrated that a highly distorted orientation was induced by a steric hindrance of the C-8 substituent, such as Cl, Br, or a methyl group. Thus, their highly strained conformation should be a key factor for the potent antibacterial activity.